NCT00739063View on ClinicalTrials.gov

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Breast Cancer

Interventions

DRUG

Tarceva

Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

OSI Pharmaceuticals

All Listed Sponsors

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00739063 - Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | Biotech Hunter | Biotech Hunter